Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588167 · ClinicalTrials.gov registry record
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
A clinical trial of Niemann-Pick Disease, Type C, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05588167 is a study of Niemann-Pick Disease, Type C that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 100 participants, below the 329-participant average among 3 other Niemann-Pick Disease, Type C trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05588167, a study of Niemann-Pick Disease, Type C, is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talking, or dementia. But symptoms can vary among different people with the disease. Some may have seizures, while others do not, for example. Some people begin showing symptoms in childhood; in others, symptoms may not appear until they are adults. Researchers want to learn more about why NPC affects people differently. This natural history study will gather data from people with NPC in order to understand more about the disease and how it affects the body. Objective: This study will create the first and largest database about NPC. Eligibility: People of any age who have NPC. Design: Participants will have blood drawn from a vein. This will happen only once. The blood will be used to analyze the participants DNA. The participants medical records will be reviewed. The study team will collect data on participants NPC diagnosis and symptoms; they will record how long participants have had each symptom. The study team will also collect data on each participants age, sex, race, height, weight, medications, and other test results. The study team will communicate with participants. They will discuss the study and answer any questions. Participants will receive up to $190.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2026-09-30 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05588167
The ClinicalTrials.gov registry entry for NCT05588167 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 3 other Niemann-Pick Disease, Type C trials with a reported enrollment target (70% lower). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Niemann-Pick Disease, Type C appearing as the primary indexed condition, and to 0 interventions.
NCT05588167 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05588167 about?
NCT05588167 is a clinical study titled "Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C". Background: Niemann-Pick type C (NPC) disease is a rare, progressive neurodegenerative disease that affects mainly the brain, liver, and spleen but also other parts of the body. There is no cure for NPC, and symptoms only get worse over time. Symptoms can include seizures, difficulty moving or talk...
What is the current status of trial NCT05588167?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-11-28. Estimated completion is 2026-09-30.
What conditions does trial NCT05588167 study?
This clinical trial studies the following conditions: Niemann-Pick Disease, Type C.
Who is sponsoring clinical trial NCT05588167?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588167 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Niemann-Pick Disease, Type C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
RECRUITING
-
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
RECRUITING · Phase 3
-
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.